New insights on the antidepressant discontinuation syndrome
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Objective: Antidepressants are at best 50–55% effective. Non‐compliance and the antidepressant discontinuation syndrome (ADS) are causally related yet poorly appreciated. While ADS is associated with most antidepressants, agomelatine seems to be devoid of such risk. We review the neurobiology and clinical consequences of antidepressant non‐compliance and the ADS. Agomelatine is presented as a counterpoint to learn more on how ADS risk is determined by pharmacokinetics and pharmacology. Design: The relevant literature is reviewed through a MEDLINE search via PubMed, focusing on agomelatine and clinical and preclinical research on ADS. Results: Altered serotonergic dysfunction appears central to ADS so that how an antidepressant targets serotonin will determine its relative risk for inducing ADS and thereby affect later treatment outcome. Low ADS risk with agomelatine versus other antidepressants can be ascribed to its unique pharmacokinetic characteristics as well as its distinctive actions on serotonin, including melatonergic, monoaminergic and glutamatergic‐nitrergic systems. Conclusions: This review raises awareness of the long‐term negative aspects of non‐compliance and inappropriate antidepressant discontinuation, and suggests possible approaches to “design‐out” a risk for ADS. It reveals intuitive and rational ideas for antidepressant drug design, and provides new thoughts on antidepressant pharmacology, ADS risk and how these affect long‐term outcome. Copyright © 2014 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 5×
“The MT1 receptor is negatively coupled to adenylyl cyclase (AC), thereby negatively modulating protein kinase A cAMP response element binding protein signalling and phospholipase Cβ activation, which is central to antidepressant activity (Manji et al., 2001; Krishnan and Nestler, 2008).”
BackgroundInfluentialThe cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182 · cited 3×
“…time-dependent neuroplastic events, not unlike that observed when an antidepressant is started up until the onset of therapeutic effects some weeks later (see Manji et al., 2001; Popoli et al., 2002; Krishnan and Nestler, 2008, for review), and which will be touched on later in this review.”
BackgroundCourse of illness, hippocampal function, and hippocampal volume in major depression
MacQueen, G. M., Campbell, S., McEwen, B. S., Macdonald, K., Amano, S., Joffe, R. T., Nahmias, C., & Young, L. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0337481100 · Cited by 980 · cited 3×
“not closely adhered to from the start (MacQueen et al., 2003).”
BackgroundInfluentialPharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Melatonin—A pleiotropic, orchestrating regulator molecule
Hardeland, R., Cardinali, D. P., Srinivasan, V., Spence, D. W., Brown, G. M., & Pandi-Perumal, S. R. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.12.004 · Cited by 843
Kendler, K. S., Thornton, L. M., & Gardner, C. O. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.8.1243 · Cited by 721 · cited 1×
“Chronic psychosocial and environmental stressors play a major role in the development of depression (Kendler et al., 2001a, 2001b), with genetic variability determining the susceptibility of the individual to developing an anxiety or mood disorder and aiding in its recovery (Harvey, 2008).”
BackgroundMeyer, J. H., Ginovart, N., Boovariwala, A., Sagrati, S., Hussey, D., Garcia, A., Young, T., Praschak-Rieder, N., Wilson, A. A., & Houle, S. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1209 · Cited by 585
How might circadian rhythms control mood? Let me count the ways
McClung, C. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.02.019 · Cited by 507
Bipolar and major depressive disorder: Neuroimaging the developmental-degenerative divide
Savitz, J., & Drevets, W. C. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.01.004 · Cited by 494
Kendler, K. S., Thornton, L. M., & Gardner, C. O. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.582 · Cited by 480
Nutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., Carrasco, J. L., & Stahl, S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106069938 · Cited by 366
McCabe, C., Mishor, Z., Cowen, P. J., & Harmer, C. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.001 · Cited by 365
Wakamatsu, H., Yoshinobu, Y., Aida, R., Moriya, T., Akiyama, M., & Shibata, S. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01483.x · Cited by 308 · cited 2×
“, 2005) and the circadian pattern of clock gene expression in hippocampal neurons (Wakamatsu et al., 2001; Jilg et al., 2010).”
BackgroundSerotonin Reuptake Inhibitor Withdrawal
Coupland, N. J., Bell, C. J., & Potokar, J. P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199610000-00003 · Cited by 303 · cited 2×
“Considering the range of serotonergic manifestations evident in ADS, especially those of a neuropsychiatric nature such as anxiety, irritability and sleep disturbances (Table 1; Coupland et al., 1996), postsynaptic 5-HT1A/2C receptors are very likely one of the central receptor systems responsible for ADS.”
BackgroundMartinotti, G., Sepede, G., Gambi, F., Di Iorio, G., De Berardis, D., Di Nicola, M., Onofrj, M., Janiri, L., & Di Giannantonio, M. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d6c25 · Cited by 276
Circadian regulation of hippocampal long-term potentiation
Chaudhury, D., Wang, L. M., & Colwell, C. S. (2005) · Journal of Biological Rhythms · doi:10.1177/0748730405276352 · Cited by 231
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214 · cited 2×
“…insomnia, tinnitus and imbalance (Table 1; Warner et al., 2006; Narayan and Haddad, 2010; Clewes, 2012), the severity of discontinuation reactions varies between individuals and across a spectrum, with some patients manifesting an isolated symptom and others a cluster of symptoms (Haddad, 2001).”
BackgroundDiscontinuation Symptoms After Treatment With Serotonin Reuptake Inhibitors: A Literature Review
Zajecka, J., Tracy, K. A., & Mitchell, S. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0702 · Cited by 209 · cited 1×
“Importantly, when antidepressants are switched, ADS from the antidepressant that has been stopped may be misdiagnosed as an adverse side effect of the newly initiated antidepressant (Zajecka et al., 1997), as has been described by Haddad and Qureshi (2000).”
BackgroundMeyer, J. H., Wilson, A. A., Sagrati, S., Miler, L., Rusjan, P., Bloomfield, P. M., Clark, M., Sacher, J., Voineskos, A. N., & Houle, S. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.156 · Cited by 182 · cited 1×
“More important, the latter anomaly persists into recovery after SRI treatment (Meyer et al., 2009), while a persistent deficit in monoamine neuromodulation may contribute to recurrence.”
BackgroundPRICE, J. S., WALLER, P. C., WOOD, S. M., & MACKAY, A. V. P. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.00498.x · Cited by 171 · cited 1×
“Furthermore, ADS can be relatively short lived or last for months (Price et al., 1996), the latter with serious ramifications for the patient.”
BackgroundSSRI-induced apathy syndrome: a clinical review
BARNHART, W. J., MAKELA, E. H., & LATOCHA, M. J. (2004) · Journal of Psychiatric Practice · doi:10.1097/00131746-200405000-00010 · Cited by 170
Discontinuation symptoms in depression and anxiety disorders
Baldwin, D. S., Montgomery, S. A., Nil, R., & Lader, M. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006358 · Cited by 140
Illness risk following rapid versus gradual discontinuation of antidepressants
Baldessarini, R. J., Tondo, L., Ghiani, C., & Lepri, B. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09060880 · Cited by 123 · cited 4×
“Over the long term, ADS can reduce the time between depressive episodes and significantly increase the risk of new episodes (Baldessarini et al., 2010).”
BackgroundInfluentialRecognising and managing antidepressant discontinuation symptoms
Haddad, P. M., & Anderson, I. M. (2007) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.105.001966 · Cited by 109
Wilson, K., & Mottram, P. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1156 · Cited by 107
Murata, Y., Kobayashi, D., Imuta, N., Haraguchi, K., Ieiri, I., Nishimura, R., Koyama, S., & Mine, K. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c8ae80 · Cited by 37 · cited 1×
“Indeed, recent evidence indicates that the C ( 1019)G polymorphism of the 5-HT1A receptor gene may be implicated in paroxetine associated ADS (Murata et al., 2010).”
BackgroundClewes, J. (2012) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.11br01218 · Cited by 16 · cited 3×
“ADS is typically associated with dizziness, nausea, headache, lethargy, low mood, insomnia, tinnitus and imbalance (Table 1; Warner et al., 2006; Narayan and Haddad, 2010; Clewes, 2012), the severity of discontinuation reactions varies between individuals and across a spectrum, with some patients manifesting an isolat…”
BackgroundTint, A., Haddad, P. M., & Anderson, I. M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107087488 · Cited by 13
Cited by
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Malhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614
Brand, S., Moller, M., & Harvey, B. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150307004545 · Cited by 95
Self-citationFramer, A. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321991274 · Cited by 73
Antidepressant Withdrawal and Rebound Phenomena
Henssler, J., Heinz, A., Brandt, L., & Bschor, T. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0355 · Cited by 50
Metadata
- Authors
- Harvey, B. H., & Slabbert, F. N.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2014-08-11
- Volume
- 29
- Issue
- 6
- Pages
- 503-516
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W1515310007
- Cited by
- 58
- References
- 28
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.